Rates of multiple myeloma, the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published by Wiley online in CANCER provides insights that may help to explain this disparity.

Immunotherapy before and after surgery improves outcomes for patients with lung cancer

Researchers find that higher bacteria levels inside tumors promote treatment resistance in head and neck cancer

Promising targeted therapies for AML and colorectal cancer

New targets identified to prevent chronic neuropathic pain after nerve injury

Scientists at the Icahn School of Medicine at Mount Sinai, in partnership with the Multiple Myeloma Research Foundation (MMRF) and in collaboration with leading institutions across the country, have helped generate the largest single-cell immune cell atlas of the bone marrow in patients with multiple myeloma, a blood cancer that, while treatable, remains incurable. The findings, published in Nature Cancer, provide unprecedented insight on immune dysfunction in myeloma and could lead to improved tools for predicting which patients are at higher risk of relapse after treatment.